AstraZeneca divests rights to established hypertension medicines
- Details
- Category: AstraZeneca
AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma (Atnahs).
Pfizer Vaccines launches global Centers of Excellence Network
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced today the launch of its Vaccines Division's Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific vaccine-preventable diseases and potentially evaluate vaccine effectiveness affecting adults.
Free "LabXchange" science education accelerator launched by Amgen Foundation and Harvard's Faculty of Arts and Sciences
- Details
- Category: Amgen
The Amgen Foundation and the Faculty of Arts and Sciences at Harvard University (Harvard FAS) today announced the global launch of LabXchange™, a free online science education platform that provides users with access to personalized instruction, virtual lab experiences and networking opportunities across the global scientific community.
Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer
- Details
- Category: AstraZeneca
AstraZeneca's Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer.
The US Food and Drug Administration (FDA) grants ODD to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US.
U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.
Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer
- Details
- Category: AstraZeneca
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted Priority Review in the US for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to 1st-line platinum-based chemotherapy with bevacizumab.
Roche and Illumina partner to broaden patient access to genomic testing
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has entered into a 15-year, non-exclusive partnership with Illumina to broaden the adoption of distributable next-generation sequencing (NGS) based testing in oncology. As the understanding of the genomic drivers of cancer evolves, NGS has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring.
More Pharma News ...
- Amgen announces global diagnostic collaborations
- Boehringer Ingelheim partners with Enleofen to develop first-in-class anti-IL-11 therapies for a range of fibrotic diseases
- Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery
- Bristol-Myers Squibb completes divestment of manufacturing facility in Anagni, Italy
- Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction
- Amgen commences strategic collaboration with BeiGene to expand oncology presence in China
- Lilly opens Phase 3 clinical trial in RET-mutant medullary thyroid cancer